PICALM and Alzheimer disease: To decipher the inconsistencies in mRNA and protein levels of PICALM observed in postmortem human AD brain samples [124], the PICALM levels in each cell type (e.g., microglia, neuron, astrocytes, oligodendrocytes, etc.)should be analyzed in large scale diverse cohorts by high throughput single cell sequencing and further validated by RT-qPCR, Western blotting, mass-spectrometry (in distinct cell-type fractions) and by in situ hybridization and/or immunohistochemistry (in sections) of postmortem human AD brain samples [167].